Completed OBSERVATIONAL NCT01752101

Identification of a Plasma Proteomic Signature for Lung Cancer

Sponsor: Integrated Diagnostics

Conditions Carcinoma Precancerous Conditions

Updated 10 times since 2017 Last updated: Jan 7, 2015 Started: Oct 31, 2012 Primary completion: Dec 31, 2014 Completion: Dec 31, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01752101, this observational or N/A phase trial focuses on Carcinoma and Precancerous Conditions and remains completed. Sponsored by Integrated Diagnostics, it has been updated 10 times since 2012, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

10 versions recorded

Sep 2024 — Present [monthly]

Completed
Jul 2024 — Sep 2024 [monthly]

Completed
Dec 2021 — Jul 2024 [monthly]

Completed
Jan 2021 — Dec 2021 [monthly]

Completed
Nov 2020 — Jan 2021 [monthly]

Completed

▶ Show 5 earlier versions

Jun 2018 — Nov 2020 [monthly]

Completed
May 2018 — Jun 2018 [monthly]

Completed
Apr 2018 — May 2018 [monthly]

Completed

Phase: NA → None
Aug 2017 — Apr 2018 [monthly]

Completed NA
Jan 2017 — Aug 2017 [monthly]

Completed NA

First recorded

Oct 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Integrated Diagnostics

Data source: Integrated Diagnostics

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Anniston, United States , Baltimore, United States , Burlington, United States , Cincinnati, United States , Dallas, United States , Danville, United States , Detroit, United States , Miami, United States , Murray, United States , Rochester, United States and 2 more locations